Equities analysts expect Intec Pharma (NASDAQ:NTEC) to announce ($0.30) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Intec Pharma’s earnings, with estimates ranging from ($0.32) to ($0.25). Intec Pharma reported earnings of ($0.40) per share in the same quarter last year, which would indicate a positive year over year growth rate of 25%. The firm is expected to announce its next quarterly earnings results on Wednesday, November 21st.
On average, analysts expect that Intec Pharma will report full year earnings of ($1.36) per share for the current fiscal year, with EPS estimates ranging from ($1.43) to ($1.26). For the next year, analysts forecast that the company will post earnings of ($0.99) per share, with EPS estimates ranging from ($1.05) to ($0.90). Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow Intec Pharma.
Intec Pharma (NASDAQ:NTEC) last announced its quarterly earnings results on Wednesday, August 15th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.02).
NTEC has been the topic of several research analyst reports. Zacks Investment Research cut shares of Intec Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, July 25th. Oppenheimer set a $15.00 target price on shares of Intec Pharma and gave the company a “buy” rating in a research note on Wednesday, August 15th. HC Wainwright set a $16.00 target price on shares of Intec Pharma and gave the company a “buy” rating in a research note on Thursday, August 16th. Finally, Roth Capital initiated coverage on shares of Intec Pharma in a research note on Friday, October 5th. They set a “buy” rating and a $8.50 target price on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $11.40.
A number of institutional investors and hedge funds have recently bought and sold shares of NTEC. Harel Insurance Investments & Financial Services Ltd. bought a new position in Intec Pharma during the 2nd quarter valued at about $132,000. JPMorgan Chase & Co. bought a new position in Intec Pharma during the 1st quarter valued at about $138,000. Jane Street Group LLC bought a new position in Intec Pharma during the 1st quarter valued at about $185,000. PNC Financial Services Group Inc. bought a new position in shares of Intec Pharma in the 2nd quarter worth approximately $220,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Intec Pharma by 484.3% in the 2nd quarter. Renaissance Technologies LLC now owns 88,898 shares of the biotechnology company’s stock worth $391,000 after purchasing an additional 73,684 shares during the period. Institutional investors and hedge funds own 47.01% of the company’s stock.
NTEC opened at $5.79 on Friday. The stock has a market cap of $192.36 million, a price-to-earnings ratio of -3.51 and a beta of 0.71. Intec Pharma has a 52-week low of $3.55 and a 52-week high of $7.80.
Intec Pharma Company Profile
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Featured Story: Hedge Funds – Risk or Reward?
Get a free copy of the Zacks research report on Intec Pharma (NTEC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.